MetaVia Advances Obesity Drug Candidate with Expanded Clinical Trial

Biopharmaceutical company MetaVia has received regulatory clearance to proceed with higher-dose testing of its experimental obesity treatment, DA-1726. This authorization marks a significant step forward for the firm's lead candidate, positioning it to potentially challenge established players in the lucrative weight-loss medication sector. The news follows closely on the heels of a separate patent extension for another key asset in the company's pipeline.

Clinical Trial Progress and Mechanism

On March 18, 2026, an independent review board (IRB) granted approval for the third segment of the Phase 1 study for DA-1726. This stage will involve 40 participants and focus on evaluating various dose-escalation strategies to determine optimal tolerability at higher concentrations. The decision to pursue this path is supported by compelling data from January 2026, which indicated that a 48 mg dose administered to an earlier cohort resulted in an average weight reduction of 9.1% over a 54-day period.

MetaVia's drug candidate operates on a dual-agonist mechanism, simultaneously targeting both GLP-1 and glucagon receptors. This approach is designed not only to suppress appetite but also to elevate the body's energy expenditure. Industry observers suggest this dual action could potentially yield superior weight loss outcomes compared to therapies that solely focus on GLP-1 pathways.

Strengthening the Metabolic Portfolio

Should investors sell immediately? Or is it worth buying Neurobo Pharmaceuticals?

In a parallel development strengthening its broader metabolic disease strategy, MetaVia confirmed an extension of worldwide patent protection for its liver disease drug candidate, Vanoglipel (DA-1241). The protection is now secured until 2035, as announced on March 12, 2026. Previous clinical results for this compound have demonstrated notable improvements in liver health metrics and blood sugar control.

This focus on cardiometabolic conditions represents the core of the company's strategic shift, which was formally initiated in late 2024 when Neurobo Pharmaceuticals rebranded as MetaVia. The company is now channeling its resources entirely into these two interconnected growth areas: obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Upcoming Milestones and Timeline

The company has outlined an ambitious clinical schedule for the remainder of the year. Dosing for the first participants in the expanded DA-1726 trial is slated to commence in April 2026. MetaVia anticipates releasing comprehensive data on the drug's efficacy and safety profile during the fourth quarter of 2026, providing key insights for investors and the medical community.

Ad

Neurobo Pharmaceuticals Stock: New Analysis - 22 March

Fresh Neurobo Pharmaceuticals information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Neurobo Pharmaceuticals analysis...